Lista de obras -

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

artículo científico publicado en 2002

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

artículo científico publicado en 2005

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

artículo científico publicado en 2005

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase ⬇️

artículo científico publicado el 1 de septiembre de 2003

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

artículo científico publicado en 2007

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

artículo científico publicado en 2003

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

artículo científico publicado en 2006

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

artículo científico publicado en 2009

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells ⬇️

artículo científico publicado el 1 de octubre de 2003

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

artículo científico publicado en 2009

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

artículo científico publicado en 2004

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

artículo científico publicado en 2007

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

artículo científico publicado en 2004

Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies ⬇️

artículo científico publicado el 1 de noviembre de 2011

Emerging therapies for multiple myeloma

artículo científico publicado en 2009

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

artículo científico publicado en 2006

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

artículo científico publicado en 2005

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

artículo científico publicado en 2009

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo ⬇️

artículo científico publicado el 31 de agosto de 2012

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2003

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

artículo científico publicado en 2005

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

artículo científico publicado en 2005

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

artículo científico publicado en 2005

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2007

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

artículo científico publicado en 2020

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

artículo científico publicado en 2003

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

artículo científico publicado en 2021

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

MM-associated anemia: more than “crowding out” HSPCs ⬇️

artículo científico publicado el 27 de septiembre de 2012

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

artículo científico publicado en 2004

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

artículo científico publicado en 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

artículo científico publicado en 2002

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

artículo científico publicado en 2005

Multiple myeloma

artículo científico publicado en 2009

Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma ⬇️

artículo científico publicado el 1 de septiembre de 2012

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2006

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

artículo científico publicado en 2004

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

artículo científico publicado en 2003

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

artículo científico publicado en 2018

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2006

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

artículo científico publicado en 2007

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

artículo científico publicado en 2004

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

artículo científico publicado en 2006

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

artículo científico publicado en 2007

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

artículo científico publicado en 2002

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

artículo científico publicado en 2003

The malignant clone and the bone-marrow environment

artículo científico publicado en 2007

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

artículo científico publicado el 19 de septiembre de 2011

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2002

Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans

scientific article published on 08 December 2020

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

artículo científico publicado en 2004

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

artículo científico publicado en 2004

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

artículo científico publicado en 2004

Lista de obras de

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase ⬇️

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells ⬇️

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies ⬇️

Emerging therapies for multiple myeloma

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo ⬇️

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

MM-associated anemia: more than “crowding out” HSPCs ⬇️

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

Multiple myeloma

Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma ⬇️

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

The malignant clone and the bone-marrow environment

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells